Intrabio to conduct phase III trial in SCA6 and Episodic Ataxia Type-2
The pharmaceutical company Intrabio, who developed the recently FDA-approved drug AQNEURSA for people with Niemann-Pick Disease Type C, has announced their plans to begin a phase III trial of the […]
Intrabio to conduct phase III trial in SCA6 and Episodic Ataxia Type-2 Read More »